#AS­CO22: En­her­tu blows chemother­a­py out of the wa­ter, re­defin­ing breast can­cer sub­groups along the way

CHICA­GO — When Camille Hertz­ka found out the re­sults of a study show­ing breast can­cer drug En­her­tu cut dis­ease pro­gres­sion or death by about half, the As­traZeneca VP im­me­di­ate­ly thought of the po­ten­tial for pa­tients, some of whom are friends.

Giv­en her po­si­tion lead­ing US med­ical af­fairs for AZ’s on­col­o­gy unit, Hertz­ka of course couldn’t tell her friend with HER2-low breast can­cer the re­sults of the study, but that friend was still top of mind as the Big Phar­ma geared up to present the land­mark re­sults at the an­nu­al AS­CO meet­ing on Sun­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.